328236-46-0

Upstream product

• 328236-42-6 4-bromo-2-isopropyl phenyl methoxymethyl ether 
• 328236-44-8 2,6-dimethyl-4-(triisopropyl-silanyloxy)-benzaldehyde 
• 328236-43-7 (4-bromo-3,5-dimethylphenoxy)triisopropylsilane 
• 13154-24-0 triisopropylsilyl chloride 
• 70547-87-4 2,6-dimethyl-4-hydroxybenzaldehyde 
• 88-69-7 2-(1-methylethyl)phenol 
• 328236-45-9 3,5-dimethyl-4-(3'-isopropyl-4'-O-methoxymethylbenzylhydroxy)-O-triisopropylsilylphenol 
• 26307-50-6 4-bromo-2-isopropyl-phenol 
• 7463-51-6 4-bromo-3,5-dimethylphenol 

Downstream Products

• 328236-47-1 3,5-dimethyl-4-(3'-isopropyl-4'-O-methoxymethylbenzyl)phenol 
• 1172583-80-0 2-(4-(3-isopropyl-4-(methoxymethoxy)-5-((4-nitrophenyl)ethynyl)benzyl)-3,5-dimethylphenoxy)acetic acid 
• 446312-28-3 [4-(3-iodo-5-isopropyl-4-methoxymethoxybenzyl)-3,5-dimethylphenoxy]triisopropylsilane 
• 417871-20-6 {5'-[2,6-dimethyl-4-(triisopropylsilanyloxy)benzyl]-3-isopropyl-2-methoxymethoxyphenyl}boronic acid 
• 852948-39-1 di-N-(L-1-ethoxycarbonylethylamino)[3,5-dimethyl-4-(4'-hydroxy-3'-isopropylbenzyl)phenoxy]methylphosphonamide 
• 852948-02-8 di(pivaloyloxymethyl)[3,5-dimethyl-4-(4'-hydroxy-3'-isopropylbenzyl)phenoxy]methylphosphonate 
• 852948-38-0 di-(S-acetyl-2-thioethyl)[3,5-dimethyl-4-(4'-hydroxy-3'-isopropylbenzyl)phenoxy]methylphosphonate 
• 852949-68-9 diethyl [4,6-dimethyl-5-(4'-hydroxy-3'-iso-propyl)benzyl]benzofuran-2-phosphonate 
• 852947-39-8 [14C]-MB07344 
• 852948-13-1 [14C]-MB07811 
• 852948-12-0 (2S,4S)-2-[(3,5-dimethyl-4-(4'-hydroxy-3'-isopropylbenzyl)-phenoxy)methyl]-4-(3-chlorophenyl)-2-oxido[1,3,2]dioxaphosphane 
• 328236-48-2 [3,5-dimethyl-4-(3'-isopropyl-4'-O-methoxymethylbenzyl)phenoxy]tert-butylacetate 
• 211110-63-3 sobetirome 
• 417872-62-9 C₅₀H₇₁N₃O₆SSi 

Relevant academic research and scientific papers

Chasing the Elusive Benzofuran Impurity of the THR Antagonist NH-3: Synthesis, Isotope Labeling, and Biological Activity

We have synthesized and established the structure of a long-suspected, but hitherto unknown, benzofuran side product (EBI) formed during the synthesis of NH-3. Understanding the mechanism of its formation has enabled isotope (D) labeling. We further devel

Novel Phosphinic Acid-Containing Thyromimetics

The present invention relates to compounds of phosphonic acid-containing T3 mimetics and monoesters thereof, stereoisomers, pharmaceutically acceptable salts, co-crystals, and prodrugs thereof and pharmaceutically acceptable salts and co-crystals of the prodrugs, as well as their preparation and uses for preventing and/or treating metabolic diseases such as obesity, NASH, hypercholesterolemia and hyperlipidemia, as well as associated conditions such as atherosclerosis, coronary heart disease, impaired glucose tolerance, metabolic syndrome x and diabetes.

Synthesis and biological evaluation of a series of liver-selective phosphonic acid thyroid hormone receptor agonists and their prodrugs

Phosphonic acid (PA) thyroid hormone receptor (TR) agonists were synthesized to exploit the poor distribution of PA-based drugs to extrahepatic tissues and thereby to improve the therapeutic index. Nine PAs showed excellent TR binding affinities (TRβ

NOVEL PHOSPHORUS-CONTAINING THYROMIMETICS

The present invention relates to compounds of phosphonic acid containing T3 mimetics, stereoisomers, pharmaceutically acceptable salts, co-crystals, and prodrugs thereof and pharmaceutically acceptable salts and co-crystals of the prodrugs, as well as their preparation and uses for preventing and/or treating metabolic diseases such as obesity, NASH, hypercholesterolemia and hyperlipidemia, as well as associated conditions such as atherosclerosis, coronary heart disease, impaired glucose tolerance, metabolic syndromex and diabetes.

Improved synthesis of the iodine-free thyromimetic GC-1

Synthesis of the TRβ-selective thyromimetic GC-1 has been improved using methoxymethyl (MOM) and triisopropylsilyl (TiPS) substituents as phenolic protecting groups. The new synthetic route is adaptable to analogue design. (C) 2000 Elsevier Science Ltd.